Ligand Pharmaceuticals | LGND - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Agenus USD 19.81M 293.94M 2025-12
Amgen USD 5.9B 773M 2025-12
Anika Therapeutics USD 29.97M 116.84M 2025-12
Arrowhead Research USD 223.22M 10.86M 2025-12
Baxter International USD 3.19B 554.4M 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Enviri Corporation USD 590.29M 229.2M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Glaxosmithkline GBP 9.17B 1.4B 2025-12
Heron Therapeutics USD 40.55M 1.46M 2025-12
Insmed USD 513.55M 109.86M 2025-12
Intrexon USD 61.56M 26.1M 2024-06
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Karyopharm Therapeutics USD 61.82M 3.24M 2024-12
Ligand Pharmaceuticals USD 8.29M 32.17M 2025-09
MacroGenics USD 53.32M 13.68M 2025-12
Merck USD 10.16B 558M 2025-12
Pacira USD 193.68M 27.32M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Veracyte USD 116M 7.24M 2025-12